Glucagon-like peptide-1 receptor agonists (GLP-1RAs), widely used for obesity and type 2 diabetes, have demonstrated pleiotropic benefits that include reductions in systemic inflammation, improvement of myocardial energetics, and attenuation of adverse structural remodeling. This evidence concerns the gene GLP1R and obesity disorder.